SlowMist Issues Security Alert on Potential New Risks Following Ethereum Pectra Upgrade
On May 8, the security company SlowMist issued a reminder about potential new risks brought by the new features after the Ethereum Pectra upgrade:
For users: Private key protection should always be a top priority. Be aware that the contract code at the same contract address on different chains may not always be the same. Understand the details of the delegation target before proceeding;
For wallet providers: Check whether the delegation chain matches the current network, and remind users of the risks associated with using delegation signatures with chainID 0, as such signatures may be replayed on different chains. Display the target contract when users sign a delegation to reduce the risk of phishing attacks;
For developers: Ensure permission checks are performed during wallet initialization (e.g., verifying the signature address through ecrecover), and follow the namespace formula proposed in ERC-7201 to mitigate storage conflicts. Do not assume that tx.origin is always an externally owned account (EOA); using msg.sender == tx.origin as a means to defend against reentrancy attacks will no longer be effective. Ensure that the target contract delegated by the user implements the necessary callback functions to ensure compatibility with mainstream tokens.
For centralized trading platforms: Conduct tracking checks on deposits to reduce the risk of false deposits from smart contracts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
